Sanofi-Aventis' Menactra Demonstrates Noninferiority To Menomune, FDA Says

The meningococcal vaccine Menactra met its primary safety endpoint of noninferiority in severe systemic adverse events. Sanofi-Aventis failed to show lot consistency within predefined equivalence limits, FDA says.